Redesigned

Abgentis News

  • Honorary appointment at the University of Birmingham

    Abgentis' founder Lloyd Czaplewski has been appointed as an Honorary Senior Research Fellow in the School of Immunity & Infection within the College of Medical & Dental Sciences at the University of Birmingham, U.K.

    Recently Dr Czaplewski located Abgentis Limited, the antibiotic re-engineering Company, at the University of Birmingham Research Park. This Honorary position will provide exciting opportunities to develop collaborative projects that build on the excellent platforms developed by Abgentis and on Birmingham's world-leading research and increasingly translational focus on microbiology and infection.

    Read more...

    0 comments

  • EARLY ADVANTAGE FUND INVESTS £75,000 IN ABGENTIS

    A company creating new treatments for life-threatening and drug-resistant bacterial infections has received a cash injection from Midven’s Early Advantage Fund.

    Abgentis, based at the Birmingham Research Park, will receive £75,000 from the Fund in up to three milestone-driven tranches to establish proof of concept.

    The company is working to modify the antibiotic compound novobiocin, originally used to treat infections in the 1960s but which was replaced by drugs that were more competitive at the time.

    “Now, however, the clinical landscape has changed,” said Lloyd Czaplewski, who founded Abgentis. “There is resistance to these replacements and more recent clinical evaluation of novobiocin in oncology confirms that it is well tolerated in man.”

    He said that new scientific insights into how novobiocin works provided an opportunity to re-engineer the drug to create a new and valuable antibiotic therapy. “Antibiotics have been a low priority for development over the last decade but the clinical need is increasing with wide-spread drug-resistance, an ageing population and new markets in developing countries,” said Dr Czaplewski.

    The £75,000 comes through Midven’s Early Advantage Fund, which provides investment for small, high growth businesses at start-up and early stage in the West Midlands, and has already helped secure additional private investment for the company, which plans to raise further funding this autumn. A business angel has also invested in this round.

    The money will be used to generate a package of pre-clinical proof-of-concept information to support the licensing of the programme to established pharmaceutical companies.

    Dr Andrew Muir, a director of Midven and investment director of the Early Advantage Fund who has joined the Board of Abgentis said: “Lloyd has an excellent understanding of the technology and needs in the field of novel antibacterials and our funding will enable the company to validate its novel approach”

    Professor Lawrence Young, Pro-Vice-Chancellor and Head of College of Medical Sciences at the University of Birmingham commented “The University of Birmingham is very pleased to be hosting Abgentis on the Birmingham Research Park. This will provide exciting opportunities to develop collaborative projects that build on the excellent platforms developed by Abgentis and on our world-leading research on microbiology and infection”.

    About Midven Limited/Early Advantage

    Midven Limited is a privately owned commercial venture capital fund manager with a successful track record of investing in and exiting from small and medium-sized enterprises in the Midlands. Midven manages five funds representing £61m under management. The funds have invested in a wide variety of sectors, including software, biotechnology, healthcare, engineering, manufacturing and distribution. Midven’s £8m Early Advantage fund provides investment for small, high growth businesses at start-up and early-stage in the West Midlands.

    For more information contact:

    Mark Whitehouse, Clarke Associates – Telephone: 01564 826653

    Dr Andrew Muir, Midven Limited – Telephone: 0121 710 1990

    Dr Lloyd Czaplewski, Abgentis Limited – Telephone: 07836 554231 www.abgentis.com

    Read more...

    0 comments

  • Gonorrhoea achieves superbug status

    The World Health Organisation announced that urgent action is required to prevent the spread of untreatable gonorrhoea

    "Millions of people with gonorrhoea may be at risk of running out of treatment options unless urgent action is taken, according WHO. Already several countries, including Australia, France, Japan, Norway, Sweden and the United Kingdom are reporting cases of resistance to cephalosporin antibiotics – the last treatment option against gonorrhoea. Every year an estimated 106 million people are infected with gonorrhoea, which is transmitted sexually."

    http://www.who.int/mediacentre/news/notes/2012/gonorrhoea_20120606/en/index.html

    Abgentis' IV/Oral antibacterials are designed to address this crisis to provide a new therapy to treat sexually transmitted bacterial infections, including those resistant to current drugs

    Read more...

    0 comments

  • Antibacterial DNA supercoiling inhibitors

    The Royal Society of Chemistry's Designing Multi-Target Drugs provides a valuable resource for those interested in creating novel therapies for complex diseases. The chapter on anti-bacterial DNA supercoiling inhibitors "Ethyl Urea Inhibitors of the Bacterial Type II Topoisomerases DNA Gyrase (GyrB) and Topoisomerase IV (ParE)" by Stephen P. East, Lloyd G. Czaplewski and David J. Haydon will be particularly useful for those involved in or starting out in antibacterial drug discovery

    http://pubs.rsc.org/en/content/chapter/bk9781849733625-00335/978-1-84973-491-2

    Read more...

    0 comments

  • Abgentis Limited

    Abgentis Limited created to deliver novel antibacterials to treat life-threatening and chronic bacterial infections.

    Read more...

Abgentis News

You are viewing the text version of this site.

To view the full version please install the Adobe Flash Player and ensure your web browser has JavaScript enabled.

Need help? check the requirements page.


Get Flash Player